SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories reports Profit after tax of Rs 1514.80 Mln, in the March 2021 quarter

28 May 2021 Evaluate
With no major difference for the quarter endedMarch 2021 , the total revenue stood at Rs. 10409.20  millions.A humble growth in net profit of 18.57% reported in the quarter ended March 2021 to Rs. 1514.80  millions from Rs. 1277.60 millions.The company reported a good operating profit of 2365.50 millions compared to 2060.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 10409.20 10047.90 3.60 51391.60 43674.30 17.67 51391.60 43674.30 17.67
Other Income 199.10 133.00 49.70 622.40 646.90 -3.79 622.40 646.90 -3.79
PBIDT 2365.50 2060.20 14.82 15758.20 9794.50 60.89 15758.20 9794.50 60.89
Interest 23.10 34.70 -33.43 81.40 157.90 -48.45 81.40 157.90 -48.45
PBDT 2342.40 2025.50 15.65 15676.80 9636.60 62.68 15676.80 9636.60 62.68
Depreciation 485.70 453.80 7.03 1877.20 1786.90 5.05 1877.20 1786.90 5.05
PBT 1856.70 1571.70 18.13 13799.60 7849.70 75.80 13799.60 7849.70 75.80
TAX 341.90 294.10 16.25 2391.90 1325.10 80.51 2391.90 1325.10 80.51
Deferred Tax -20.90 12.30 -269.92 -57.90 -54.70 5.85 -57.90 -54.70 5.85
PAT 1514.80 1277.60 18.57 11407.70 6524.60 74.84 11407.70 6524.60 74.84
Equity 253.70 252.70 0.40 253.70 252.70 0.40 253.70 252.70 0.40
PBIDTM(%) 22.73 20.50 10.83 30.66 22.43 36.73 30.66 22.43 36.73

Ipca Laboratories Share Price

1568.65 4.95 (0.32%)
07-May-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1829.70
Dr. Reddys Lab 1305.95
Cipla 1370.75
Zydus Lifesciences 939.00
Lupin 2469.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×